Search

Your search keyword '"Changju Qu"' showing total 2 results
Start Over Author "Changju Qu" Publisher american society for clinical investigation
2 results on '"Changju Qu"'

1. Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma

Author

Liqing Kang, Caixia Li, Jin Zhou, Xiuli Sun, Xiaochen Chen, Zhengming Jin, Jia Chen, Ting Xu, Changfeng Zhang, Nan Xu, Pu Wang, Xiangping Zong, Jingwen Tan, Changju Qu, Xiaoyan Lou, Ying Zhang, Zhen Yang, Haiwen Huang, Minghao Li, Lei Yu, and Depei Wu

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Receptors, Antigen, T-Cell, Kaplan-Meier Estimate, Single Center, Gastroenterology, Immunotherapy, Adoptive, Transplantation, Autologous, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Internal medicine, Medicine, Humans, Prospective Studies, Adverse effect, Aged, Bone Marrow Transplantation, Aged, 80 and over, Cytopenia, Hematology, business.industry, Standard treatment, Lymphoma, Non-Hodgkin, Hematopoietic Stem Cell Transplantation, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Transplantation, Cytokine release syndrome, 030104 developmental biology, 030220 oncology & carcinogenesis, Multivariate Analysis, Female, Clinical Medicine, business
Abstract

BACKGROUND: Autologous stem cell transplantation (ASCT) is the standard treatment for refractory/relapsed B cell non-Hodgkin’s lymphoma (R/R B-NHL), whereas chimeric antigen receptor T (CAR-T) therapy targeting CD19 is emerging as an alternative strategy. Here, we report a comparative analysis of the 2 strategies in a single center. METHODS: We performed a prospective, single-arm study of CAR-T therapy in 29 patients with R/R B-NHL and compared the outcomes with 27 contemporaneous patients who received ASCT. NHL was diagnosed by histopathologic assessments, and the safety and efficacy of treatments were compared. RESULTS: The CAR-T group exhibited better rates of complete response (CR) (48.0% vs. 20.8%, P = 0.046) and 1-year overall survival (OS) (74.4% vs. 44.5%, P = 0.044) compared with the ASCT group. Subpopulation analysis showed that patients with International Prognostic Index scores of at least 3 achieved a significantly higher objective response rate and CR rate in the CAR-T group than in the ASCT group (ORR 72.0% vs. 10.0%, P = 0.002, and CR 38.9% vs. 0%, P = 0.030, respectively). The most common severe adverse events in the CAR-T group were cytokine release syndrome, neurotoxicity, and infection compared with cytopenia, gastrointestinal toxicity, and infection in the ASCT group. Additionally, the incidence of nonhematologic severe adverse events was markedly lower in the CAR-T group than in the ASCT group (20.7% vs. 48.1%, P = 0.030). CONCLUSION: CAR-T therapy exhibited superior clinical outcomes in safety and efficacy over ASCT in patients with R/R B-NHL, suggesting that CAR-T may be a recommended alternative to ASCT. TRIAL REGISTRATION: ClinicalTrials.gov NCT03196830. FUNDING: Funding was supplied by UniCar Therapy, National Natural Science Foundation of China (81730003), National Science and Technology Major Project (2017ZX09304021), and Science Planning Project of Suzhou (sys2018049).

Published
2019

2. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers.

Author

Ruiying Zhao, Yeung, Sai-Ching J., Jian Chen, Iwakuma, Tomoo, Chun-Hui Su, Bo Chen, Changju Qu, Fanmao Zhang, You-Tzung Chen, Yu-Li Lin, Dung-Fang Lee, Feng Jin, Rui Zhu,8, Shaikenov, Tattym, Sarbassov, Dos, Sahin, Aysegul, Huamin Wang, Hua Wang, Chien-Chen Lai, and Fuu-Jen Tsai

Subjects
*CANCER research, *EMBRYOLOGY, *GENE expression, *BREAST cancer, *CARCINOGENESIS, *GENETIC mutation, *BIOLOGICAL rhythms, *LABORATORY mice, *PROTEIN metabolism, *ANIMALS, *BIOCHEMISTRY, *BREAST tumors, *CELL lines, *CELLULAR signal transduction, *GENES, *PHENOMENOLOGY, *MICE, *PROTEINS, *PROTEOLYTIC enzymes, *RESEARCH funding, *THYROID gland
Abstract

The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response. Its role in tumor development, however, remains unclear. Here, we have shown that the COP9 subunit 6 (CSN6) gene is amplified in human breast cancer specimens, and the CSN6 protein is upregulated in human breast and thyroid tumors. CSN6 expression positively correlated with expression of murine double minute 2 (MDM2), a potent negative regulator of the p53 tumor suppressor. Expression of CSN6 appeared to prevent MDM2 autoubiquitination at lysine 364, resulting in stabilization of MDM2 and degradation of p53. Mice in which Csn6 was deleted died early in embryogenesis (E7.5). Embryos lacking both Csn6 and p53 survived to later in embryonic development (E10.5), which suggests that loss of p53 could partially rescue the effect of loss of Csn6. Mice heterozygous for Csn6 were sensitized to γ-irradiation-induced, p53-dependent apoptosis in both the thymus and the developing CNS. These mice were also less susceptible than wild-type mice to γ-irradiation-induced tumorigenesis. These results suggest that loss of CSN6 enhances p53-mediated tumor suppression in vivo and that CSN6 plays an important role in regulating DNA damage-associated apoptosis and tumorigenesis through control of the MDM2-p53 signaling pathway. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results